Trends in post-relapse survival in Hodgkin lymphoma

Talha Badar, MD, Medical College of Wisconsin, Milwaukee, WI, discusses trends in post-relapse survival in classic Hodgkin lymphoma. Specifically discussed is the advent of novel agents such as brentuximab vedotin and the resulting improvements in outcomes. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).